<DOC>
	<DOCNO>NCT01145417</DOCNO>
	<brief_summary>This study examine safety pregabalin 6 month period patient neuropathic pain associate HIV infection extension another trial test efficacy pregabalin .</brief_summary>
	<brief_title>Pregabalin Trial In HIV Neuropathic Pain</brief_title>
	<detailed_description>The parent double blind study stop interim analysis due lack efficacy therefore open label extension study also terminate simultaneously April 2 , 2012 ; termination unrelated safety finding could impact patient health .</detailed_description>
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Pregabalin</mesh_term>
	<criteria>Subjects participate precede A0081244 doubleblind trial complete least Visit 9 trial . Subjects painful distal sensory polyneuropathy ( DSP ) interest treatment base investigator 's clinical judgment . Subjects acceptable tolerability study drug A0081244 . Clinically significant unstable condition , opinion investigator , would compromise participation study . This include , example , medical condition , limit : hepatic , renal , respiratory , hematological , immunological , cardiovascular disease , arrhythmia , inflammatory rheumatologic disease , active infection , symptomatic peripheral vascular disease , psychiatric illness , untreated endocrine disorder . Other severe acute chronic medical psychiatric condition laboratory abnormality may increase risk associate study participation investigational product administration may interfere interpretation study result , judgment investigator , would make subject inappropriate entry study . Active Acquired Immune Deficiency Syndrome ( AIDS ) define Opportunistic Infection ( OI ) require hospitalization .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2013</verification_date>
	<keyword>peripheral neuropathic pain</keyword>
	<keyword>pregabalin</keyword>
	<keyword>safety</keyword>
</DOC>